Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Kennedy Dialysis Center
mi
from
Voorhees, NJ
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Kennedy Dialysis Center
mi
from
Voorhees, NJ
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Trude Weishaupt Memorial Dialysis Center
mi
from
Fresh Meadows, NY
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Trude Weishaupt Memorial Dialysis Center
mi
from
Fresh Meadows, NY
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Wake Dialysis Clinic
mi
from
Raleigh, NC
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Wake Dialysis Clinic
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Wake Nephrology Associates PA
mi
from
Raleigh, NC
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Wake Nephrology Associates PA
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
DCI McMillan
mi
from
Cincinnati, OH
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
DCI McMillan
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Innovative Dialysis of Toledo
mi
from
Toledo, OH
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Innovative Dialysis of Toledo
mi
from
Toledo, OH
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Toledo Hospital (Promedica Health System)
mi
from
Toledo, OH
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Toledo Hospital (Promedica Health System)
mi
from
Toledo, OH
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Alexis Dialysis Center
mi
from
Toledo, OH
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Alexis Dialysis Center
mi
from
Toledo, OH
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Wildwood Dialysis Center
mi
from
Toledo, OH
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Wildwood Dialysis Center
mi
from
Toledo, OH
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
meadville Dialysis
mi
from
Meadville, PA
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
meadville Dialysis
mi
from
Meadville, PA
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
The Center for Hypertension and Nephrology Care
mi
from
Meadville, PA
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
The Center for Hypertension and Nephrology Care
mi
from
Meadville, PA
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Fresenius Medical Care
mi
from
Knoxville, TN
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Fresenius Medical Care
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Cedar Bluff Dialysis
mi
from
Knoxville, TN
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Cedar Bluff Dialysis
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Knoxville Kidney Center PLLC
mi
from
Knoxville, TN
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Knoxville Kidney Center PLLC
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Fresenius Medical Care - Austin North Dialysis
mi
from
Austin, TX
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Fresenius Medical Care - Austin North Dialysis
mi
from
Austin, TX
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Research Management, Inc
mi
from
Austin, TX
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Research Management, Inc
mi
from
Austin, TX
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Fresenius Medical Care - Cedar Park
mi
from
Cedar Park, TX
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Fresenius Medical Care - Cedar Park
mi
from
Cedar Park, TX
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Grand Prairie Dialysis Center
mi
from
Grand Prairie, TX
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Grand Prairie Dialysis Center
mi
from
Grand Prairie, TX
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Grand Prairie, TX
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Grand Prairie, TX
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Mission Bend Dialysis
mi
from
Houston, TX
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Mission Bend Dialysis
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Southwest Houston Research, Ltd
mi
from
Houston, TX
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Southwest Houston Research, Ltd
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
SNG Dialysis Center of Lufkin
mi
from
Lufkin, TX
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
SNG Dialysis Center of Lufkin
mi
from
Lufkin, TX
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
San Antonio Kidney Disease Center Physicians Group
mi
from
San Antonio, TX
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
San Antonio Kidney Disease Center Physicians Group
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Las Palmas Davita Dialysis Center
mi
from
San Antonio, TX
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Las Palmas Davita Dialysis Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
ARA Mechanicsville Dialysis
mi
from
Mechanicsville, VA
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
ARA Mechanicsville Dialysis
mi
from
Mechanicsville, VA
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
Nephrology Specialists, P.C
mi
from
Mechanicsville, VA
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
Nephrology Specialists, P.C
mi
from
Mechanicsville, VA
Click here to add this to my saved trials
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated:  12/31/1969
ARA South Laburnum Dialysis
mi
from
Richmond, VA
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status: Enrolling
Updated: 12/31/1969
ARA South Laburnum Dialysis
mi
from
Richmond, VA
Click here to add this to my saved trials
N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Use of Biomarkers to Optimize Fluid Dosing,CRRT Initiation and Discontinuation in Pediatric ICU Patients With AKI
Use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) to Optimize Fluid Dosing, Continuous Renal Replacement Therapy (CRRT) Initiation and Discontinuation in Critically Ill Children With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Use of Biomarkers to Optimize Fluid Dosing,CRRT Initiation and Discontinuation in Pediatric ICU Patients With AKI
Use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) to Optimize Fluid Dosing, Continuous Renal Replacement Therapy (CRRT) Initiation and Discontinuation in Critically Ill Children With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Use of Biomarkers to Optimize Fluid Dosing,CRRT Initiation and Discontinuation in Pediatric ICU Patients With AKI
Use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) to Optimize Fluid Dosing, Continuous Renal Replacement Therapy (CRRT) Initiation and Discontinuation in Critically Ill Children With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Use of Biomarkers to Optimize Fluid Dosing,CRRT Initiation and Discontinuation in Pediatric ICU Patients With AKI
Use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) to Optimize Fluid Dosing, Continuous Renal Replacement Therapy (CRRT) Initiation and Discontinuation in Critically Ill Children With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens
Impact of Two Prednisone-free Maintenance Immunosuppressive Regimens With Reduced Dose FK506+Everolimus vs. Standard Dose Tacrolimus (FK506)+ Mycophenolate Mofetil (MMF) on Subpopulation of T and B Cells, Renal Allograft Function and Gene Expression Profiles in Renal Allograft Biopsies at 12 Months Post-transplant. Prospective Single Center Study in Recipients of Renal Transplant Allograft.
Status: Enrolling
Updated:  12/31/1969
Northwestern Memorial Hospital
mi
from
Chicago, IL
Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens
Impact of Two Prednisone-free Maintenance Immunosuppressive Regimens With Reduced Dose FK506+Everolimus vs. Standard Dose Tacrolimus (FK506)+ Mycophenolate Mofetil (MMF) on Subpopulation of T and B Cells, Renal Allograft Function and Gene Expression Profiles in Renal Allograft Biopsies at 12 Months Post-transplant. Prospective Single Center Study in Recipients of Renal Transplant Allograft.
Status: Enrolling
Updated: 12/31/1969
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Anniston, AL
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Anniston, AL
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Huntsville, AL
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mobile, AL
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mobile, AL
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Montgomery, AL
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Montgomery, AL
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Goodyear, AZ
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Peoria, AZ
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Peoria, AZ
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tempe, AZ
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tempe, AZ
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Alhambra, CA
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Alhambra, CA
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Anaheim, CA
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Azusa, CA
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Azusa, CA
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bakersfield, CA
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bakersfield, CA
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bell Gardens, CA
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bell Gardens, CA
Click here to add this to my saved trials
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Beverly Hills, CA
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials